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Influence of Previous Chemotherapy on the Efficacy of
Subsequent Docetaxel Therapy in Advanced Non-small Cell
Lung Cancer Patients
Yasushi Goto, MD, Ikuo Sekine, MD, PhD, Kazuhiko Yamada, MD, Hiroshi Nokihara, MD, PhD,
Noboru Yamamoto, MD, PhD, Hideo Kunitoh, MD, PhD, Yuichiro Ohe, MD, PhD,
and Tomohide Tamura, MD
Purpose: To identify factors, particularly the previous use of pac-
litaxel, that might influence the efficacy of subsequent docetaxel
therapy.
Patients and Methods: The patient characteristics, responses, and
survivals were compared between the two groups that had received
a combination of carboplatin and paclitaxel (group P), and a com-
bination of a platinum and an agent other than paclitaxel (group NP).
Results: A total of 227 patients (127 in group P, and 100 in group
NP) were recruited from a hospital-based registry. Two hundred
twenty patients were evaluated for the survival, and 210 patients
were evaluated for the response of docetaxel therapy. The response
rate to docetaxel therapy (14.2% versus 16.0%, p  0.702) or the
median survival time (10.9 months versus 11.1 month, p  0.567)
did not differ between groups P and NP. The results of multivariate
analysis, adjusted for sex, age, and performance status at the start of
docetaxel therapy, showed that not the regimen per se, but the
response to previous chemotherapy significantly influenced the re-
sponse rate of docetaxel therapy (odds ratio [OR]: 1.38, 95%
confidential interval [CI]: 0.63–3.01; and OR: 2.93, 95% CI: 1.28–
6.72, respectively). As for the overall survival, neither the response
to nor the previous chemotherapy regimen had any impact (hazard
ration [HR]: 0.90, 95% CI 0.66–1.22; HR 0.88, 95% CI 0.65–1.20,
respectively).
Conclusion: The previous use of paclitaxel had no impact on the
response or survival to subsequent docetaxel therapy. In contrast, the
response to previous chemotherapy had a predictive value in relation
to responses to subsequent docetaxel therapy in patients with ad-
vanced non-small cell lung cancer.
Key Words: Non-small cell lung cancer, Second-line chemother-
apy, Docetaxel.
(J Thorac Oncol. 2008;3: 412–416)
Lung cancer is a leading cause of cancer-related deathsworldwide.1 Non-small cell lung cancer (NSCLC) ac-
counts for approximately 80% of all cases of lung cancer. For
chemotherapy-naive, patients with advanced NSCLC, with a
good performance status (PS), platinum -based chemotherapy
has been shown to offer a modest survival benefit over best
supportive care alone.2,3 A high proportion of patients, how-
ever, shows disease relapse after initial clinical responses, or
progress during the chemotherapy. Thus, a large percentage
of patients is moved on to second-line chemotherapy, even
though it should only be considered in selected patients with
a good PS.4
In the landmark study by Shepherd et al., second-line
docetaxel thearpy was demonstrated to improve the outcome
over best supportive care alone in patients with a history of
previous chemotherapy.5 Since then, a number of agents have
been introduced as effective agents for the second-line set-
ting6–8; however, the impact of previous chemotherapy on the
efficacy of subsequent chemotherapy has not been established.
In relation to small-cell lung cancer, the response of
tumors to first-line therapy and recurrence more than 3
months after completion of the initial therapy is often referred
to as “sensitive relapse,” and absence of tumor response, tumor
progression through treatment, or tumor recurrence within 3
months of discontinuation of initial therapy is termed “refrac-
tory” disease. Although both are grouped together in most
second-line clinical trials, their prognosis and response to
salvage therapy have been shown to be different.9,10 There-
fore, in patients with small-cell lung cancer, the efficacy of
previous chemotherapy has a significant impact on selection
of the subsequent chemotherapy. Whether this relationship
between first-and second-line chemotherapy would also apply
to cases of NSCLC has not yet been clarified.
In this study, we attempted to identify factors, particu-
larly the previous use of paclitaxel, that might influence the
response to subsequent docetaxel therapy in patients with
NSCLC. Towards this objective, we divided our patients into
two groups according to the previous regimen received.
PATIENTS AND METHODS
We evaluated the patients with histologically or cyto-
logically proven unresectable locally advanced or metastatic
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NSCLC, who had received a platinum-containing chemother-
apy, and subsequently received docetaxel therapy. The fol-
lowing baseline pretreatment demographic and prognostic
information was extracted: age, sex, PS (Eastern Cooperative
Oncology Group scale), clinical stage at diagnosis, histology,
interval between the final administration of the previous
chemotherapy and the start of docetaxel, and response to
previous chemotherapy. The platinum-containing therapy was
continued for as long as clinical benefit could be observed.
Docetaxel was administered at the dose of 60 mg/m2 and
repeated every 3 weeks or longer. We divided these patients
into two groups by the initial regimen that they received,
namely, combined carboplatin and paclitaxel (group P), or
combination of a platinum and an agent other than paclitaxel
(group NP).
Objective responses were evaluated using standard bi-
dimensional measurements.11 Overall survival was measured
from the first day of docetaxel treatment until death or the
final day of the follow-up period, analyzed using the Kaplan-
Meier method, and compared using the log-rank test. Other
comparisons were made by 2 test, Fisher exact test, and
Wilcoxon’s test. Factors potentially associated with the effi-
cacy of docetaxel therapy were assessed by univariate and
multivariate analysis using the logistic regression model and
Cox proportional hazards model. All variables were entered in
a single step. Variables tested were sex (male versus female),
age (continuous variable), PS at the start of docetaxel therapy (0
versus 1 and 2), regimen of previous chemotherapy (group P
versus NP), interval between previous therapy and the start
docetaxel chemotherapy (continuous variable), and response to
previous chemotherapy (SD/PD versus CR/PR). Differences
were considered to be significant at p 0.05. All analyses were
performed with Dr. SPSS II (SPSS Japan Inc.).
RESULTS
Patient Characteristics and Docetaxel Delivery
A total of 227 consecutive patients were recruited from
a hospital-based registry who were treated with docetaxel
after previous platinum-containing chemotherapy between
January 2001 and April 2006 at the National Cancer Center
Hospital. Of these 127 patients were classified into group P,
and 100 into group NP. Seven patients were excluded for the
analysis of survival because there was no measurable lesion
for the evaluation of response in the previous chemotherapy.
Of these 220 patients, another 10 patients were excluded for
the analysis of response to docetaxel therapy, because there
was no measurable lesion for the evaluation of response in the
subsequent docetaxel therapy. By the time of the analysis,
187 out of the 227 patients had died. The median follow-up
duration was 10.2 months (range, 0.3–66.9 months) for all
patients, and 18.9 months (range, 0.8–66.9 months) for
patients who had lost for follow up or alive at the time of
analysis.
The patient characteristics are listed in Table 1. The sex
and age distributions were similar in the two groups. Stage III
disease and a history of previous radiation therapy were
slightly predominant in group NP, because concurrent che-
moradiotherapy was only administered with the cisplatin
(CDDP) and vinorelbine regimen. The response to initial
therapy did not differ between the two groups.
In group NP, the regimens used for the prior chemo-
therapy and the number of patients treated were as follows;
CDDP and vinorelbine (n  35), combined carboplatin and
gemcitabine (n  24), CDDP and gemcitabine (n  19),
CDDP and irinotecan (n  18), and others (n  4).
The median (range) number of cycles of docetaxel
chemotherapy administered was 3 (1–17) in group P and 3
(1–13) in group NP.
Efficacy
The response data to docetaxel therapy are summarized
in Table 2. There were no significant differences between
group P and group NP in terms of the overall response rate
(15.1% versus 17.6%), “clinical benefit rate” (79.8% versus
75.6%), or median survival time (6.1 month versus 6.0
TABLE 1. Patient and Disease Characteristics in the Two
Groups
Characteristics
Group P
(N  127)
Group NP
(N  100)
pNo. (%) No. (%)
Sex
Male 90 (70.9) 79 (79.0) 0.161
Female 37 (29.1) 21 (21.0)
Age, yr
Median 58 60 0.072
Range 30–77 34–75
Performance status at the start of docetaxel therapy
0 22 (17.3) 26 (26.0) 0.262
1 101 (79.5) 72 (72.0)
2 4 (3.2) 2 (2.0)
Stage at diagnosis
III 34 (26.8) 51 (51.0) 0.002
IV 72 (56.7) 39 (39.0)
Recurrence 21 (16.5) 10 (10.0)
Histology
Adenocarcinoma 90 (70.9) 68 (68.0) 0.262
Squamous cell carcinoma 23 (18.1) 15 (15.0)
Large cell carcinoma 2 (1.6) 0 (0)
Other 12 (9.4) 17 (17.0)
Interval between the final administration of the previous
chemotherapy and the start of docetaxel (wk)
Median 17 17 0.285
Range 3–134 2–141
Response to previous chemotherapy
CR 0 (0) 2 (2.0) 0.031
PR 57 (44.9) 43 (43.0)
SD 49 (38.6) 46 (46.0)
PD 17 (13.4) 6 (6.0)
NE 4 (3.1) 3 (3.0)
Other treatment
Radiation 0 (0) 29 (29.0) 0.001
Surgery 21 (16.5) 10 (10.0) 0.149
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NE, not evaluable.
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months) (Figure 1). The response rates to docetaxel in good
and poor responders to previous chemotherapy were 21.8% and
9.4%, respectively, in group P (p  0.074), and 25.0% and
12.0%, respectively, in group NP (p  0.164). The overall
survival did not differ between the good and poor responders
(Figure 2).
The result of univariate and multivariate analysis of the
response to the docetaxel are shown in Table 3. In the
multivariate analysis adjusted for sex, age, PS at the start of
docetaxel therapy, the response to previous chemotherapy
significantly influenced the response to subsequent docetaxel
therapy (odds ratio [OR]: 2.93; 95% CI: 1.28–6.72). The
previous chemotherapy regimen (OR: 1.38; 95% CI: 0.63–
3.01), and interval between the final administration of the
previous chemotherapy and the start of docetaxel therapy
(OR: 0.4; 95% CI: 0.86–1.02) were not found to be signifi-
cant factors influencing the response to docetaxel therapy.
The impact of the responses to the previous chemotherapy
was denoted the same tendency in the analysis of each group
(OR: 3.82; 95% CI: 1.09–13.5 for group P, and OR: 2.13;
95% CI: 0.67–6.70 for group NP). The result of univariate
and multivariate analysis of the overall survival is shown in
Table 4. Neither the response to nor the regimen used in the
previous chemotherapy had significant impact. Interval be-
tween the final administration of the previous chemotherapy
and the start of docetaxel therapy were statistically significant
in the overall survival.
DISCUSSION
The purpose of this study was to evaluate the influence
of previous chemotherapy on the efficacy of subsequent
docetaxel chemotherapy. Above all, our major question was
whether the regimen of previous chemotherapy, especially
the use of paclitaxel, would have any influence on the
subsequent docetaxel therapy. In previous studies, response
to docetaxel therapy had no association with prior exposure to
or the efficacy of paclitaxel therapy, but details about the
paclitaxel treatment are not described in these reports.6,7 In
our study, by dividing patients according to the previous
regimen received, we showed that the previous use of pacli-
taxel had no impact on the response to subsequent docetaxel
therapy, and that the response to previous chemotherapy was
associated with the response to, but not to the survival, after
subsequent docetaxel therapy.
Although both paclitaxel and docetaxel are widely
used, the influence of prior use of paclitaxel on the response
to subsequent docetaxel therapy has not yet been thoroughly
reviewed in cases of NSCLC. In the TAX320 study con-
ducted by the Non-Small Cell Lung Cancer Study Group,
31% (114 of 373) of patients had a history of prior use of
paclitaxel.6 In that study, previous exposure to paclitaxel had
FIGURE 1. Overall survival classified by the previous che-
motherapy regimens. Continuous line: carboplatin and pacli-
taxel (group P, n  123); and dotted line: platinum and an
agent other than paclitaxel (group NP, n  97). Hazard ratio
(95% confidence interval): 1.09 (0.81–1.47).
TABLE 2. Summary of Docetaxel Therapy in the Two Groups
Characteristics
Group P
(N  127)
Group NP
(N  100)
pNo. (%) No. (%)
Treatment administration
Median (range) 3 1–17 3 1–13 0.596
Response to docetaxel therapy
CR 0 (0) 1 (1.0) 0.256
PR 18 (14.2) 15 (15.0)
SD 81 (63.8) 54 (54.0)
PD 24 (18.9) 22 (22.0)
NE 4 (3.1) 8 (8.0)
CR/PR 18 (14.2) 16 (16.0) 0.702
CR/PR/SD 99 (78.0) 70 (70.0) 0.173
Median survival
time, mo
(95% CI)
10.9 (7.6–14.1) 11.1 (8.6–13.5) 0.567
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NE, not evaluable.
FIGURE 2. Overall survival classified by the responses to
previous chemotherapy. Continuous line: SD/PD (n  118);
and dotted line: CR/PR (n  102). Hazard ratio (95% confi-
dence interval): 0.91 (0.68–1.23).
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no impact on the survival of patients who received docetaxel
as second-line treatment; however, neither the data of sur-
vival nor the details of paclitaxel therapy have been described
in the report. In a study comparing pemetrexed and docetaxel
in 571 patients, 153 patients (25%) had received paclitaxel.7
Although the results of the study showed that paclitaxel
sensitivity/resistance in the first-line treatment did not predict
any difference in the response between pemetrexed and
docetaxel used for second-line treatment (details not shown),
there were no data comparing the patients according to a
history of previous use of paclitaxel.7 In a study reassessing
these data, 20% (113 of 571) of patients had previously
received both paclitaxel and platinum, and the previous
chemotherapy regimen had no influence on the overall sur-
vival.12 However, the method used for the analysis, namely,
assessment of the overall population treated with docetaxel or
pemetrexed together, is inappropriate to evaluate the associ-
ation of previous paclitaxel use with the efficacy of subse-
quent docetaxel therapy. Patients who had no history of prior
taxane treatment were even excluded in some previous phase
III studies comparing docetaxel with best supportive care or
other agents as second-line treatment.5,8 In this study, by
comparing the patients according to the history of previous
use of paclitaxel, we could show specifically that exposure to
paclitaxel had no effect on efficacy of subsequent docetaxel
therapy.
Although docetaxel and paclitaxel exert their activity
via a similar mechanism of action, that is, by interfering with
microtubular function and promoting tubulin polymerization
and inhibiting the depolymerization of microtubules, the
preclinical and clinical activity profiles of the two agents have
been shown to exhibit some differences, with partial cross-
resistance.13 Preclinical studies have demonstrated docetaxel
to be a 100-fold more potent than paclitaxel in inducing bcl-2
phosphorylation and apoptotic cell death, and the cellular
uptake of docetaxel is known to be greater than that of
paclitaxel, both of which lead to greater cytotoxic activity of
docetaxel.14 There has been a phase II study of docetaxel in
breast cancer patients showing resistance to paclitaxel; ob-
jective responses were seen in 18% (8 of 44) of the patients,
and the dose or efficacy of previous paclitaxel administration
had no impact on the frequency of objective responses. This
TABLE 3. Univariate and Multivariate Analyses of the Response to Docetaxel (N  210)
Univariate Multivariate
OR 95% CI p OR 95% CI p
Entire
Response to previous chemotherapy (SD/PD vs CR/PR) 1.12 0.57–2.50 0.63 2.93 1.28–6.72 0.01
Regimen of previous chemotherapy (group P vs group NP) 0.84 0.40–1.75 0.84 1.38 0.63–3.01 0.421
Interval (with a 30-d increase) 0.97 0.91–1.05 0.48 0.94 0.86–1.02 0.14
Group P
Response to previous chemotherapy (SD/PD vs CR/PR) 2.70 0.94–7.76 0.07 2.13 0.67–6.70 0.20
Interval (with a 30-d increase) 1.04 0.96–1.12 0.39 1.01 0.92–1.11 0.06
Group NP
Response to previous chemotherapy (SD/PD vs CR/PR) 2.37 0.78–7.19 0.13 3.82 1.09–13.5 0.04
Interval (with a 30-d increase) 0.88 0.75–1.02 0.10 0.84 0.69–1.01 0.80
Multivariate analysis was adjusted for sex, age, and performance status at the start of docetaxel.
OR, odds ration; HR, hazard ration; P, carboplatin and paclitaxel; NP, platinum and an agent other than paclitaxel; Interval, days between previous therapy and the start docetaxel
chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 4. Univariate and Multivariate Analyses of Overall Survival (N  220)
Univariate Multivariate
HR 95% CI p HR 95% CI p
Entire
Response to previous chemotherapy (SD/PD vs CR/PR) 0.91 0.68–1.23 0.56 0.90 0.66–1.22 0.484
Regimen of previous chemotherapy (group P vs group NP) 1.09 0.81–1.47 0.57 0.88 0.65–1.20 0.43
Interval (with a 30-d increase) 0.97 0.94–0.99 0.01 0.96 0.94–0.99 0.01
Group P
Response to previous chemotherapy (SD/PD vs CR/PR) 0.95 0.64–1.41 0.80 0.92 0.60–1.41 0.71
Interval (with a 30-d increase) 0.98 0.94–1.02 0.32 1.01 0.92–1.11 0.13
Group NP
Response to previous chemotherapy (SD/PD vs CR/PR) 0.86 0.55–1.34 0.86 0.89 0.57–1.40 0.63
Interval (with a 30-d increase) 0.96 0.92–0.99 0.02 0.84 0.69–1.01 0.03
Multivariate analysis was adjusted for sex, age, and performance status at the start of docetaxel.
OR, odds ration; HR, hazard ration; P, carboplatin and paclitaxel; NP, platinum and an agent other than paclitaxel; Interval, days between previous therapy and the start docetaxel
chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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indicates that there was perhaps a partial cross-resistance
between the two agents in patients of breast cancer.15 Our
study results indicate that this might also be the case in
patients of NSCLC.
One of the tentative factors for better survival following
second-line chemotherapy is the interval elapsed after the
previous chemotherapy. This factor is a possible sign of
efficacy of previous chemotherapy, but in the analysis of
survival, it is difficult to distinguish whether this factor
influences the response to chemotherapy or represents the
characteristics of the disease in an individual. Therefore, the
interval between two chemotherapy sessions has not been
well established as a factor potentially influencing the re-
sponse in previous studies on NSCLC patients.5–8,16,17 Some
of the studies showed that a longer interval from the last
chemotherapy was significantly associated with increased
survival.7,12 In our study, interval between two chemothera-
pies was associated with the overall survival but not with
response, which suggests that this factor have little influence
on the antitumor activity of docetaxel therapy, but is repre-
senting the characteristics of the tumor.
Difference in the proportions of patients receiving surgery
or radiation therapy between the two groups may be a big
concern. These local therapies, however, should have only a
small influence, if any, because all patients in this study had a
metastatic disease at the time of recurrence and start of docetaxel
therapy. Although responses to previous chemotherapy in
patients treated with chemoradiotherapy could not be evalu-
ated in the same way as the patients treated with chemother-
apy alone, the response rates to previous chemotherapy did
not differ between the groups P and NP (44.9% in group P,
and 45.0% in group NP). Thus, we believe that these popu-
lations were appropriately included in our study.
In conclusion, the results of our study showed that
docetaxel therapy was similarly active in patients with
NSCLC, who had previously been treated with paclitaxel, and
the response to previous chemotherapy was predictive of the
response to subsequent docetaxel therapy. In the future, many
promising agents, whether cytotoxic or molecule-targeted
agents, may be developed for the second-line treatment of
NSCLC. In the era of abundantly available agents, it will be
meaningful to know which patients are likely to derive the
most benefit from a particular agent. The results of this study
are expected to be helpful for the selection of patients with
advanced NSCLC who would benefit from docetaxel therapy.
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